In SELECT, semaglutide was associated with a 41% reduction in major CV events within 6 months — ie, before weight loss or ...

Although the immediate market response was negative, most pharmaceutical stocks recovered after Wall Street analysts ...

AAN conference featured the latest research and developments in neurological disorders like Alzheimer's disease, epilepsy and ...

Fremanezumab reduced migraine attacks and depression symptoms in migraine patients with major depressive disorder.

New Haven-based Arvinas will lay off 131 employees, with 92 in Connecticut, as part of a major workforce reduction.

More than a year after it was rejected by the FDA, Satsuma Pharma's intranasal migraine therapy Atzumi (formerly STS101) has ...

DelveInsight’s “Obsessive Compulsive Disorder Treatment Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of the Obsessive Compulsive Disorder, ...

Pfizer recently said it wouldn't continue development of its weight loss candidate danuglipron, a once-daily pill, after a patient in a clinical trial experienced liver injury -- the problem ...

After years of falling Covid treatment sales, lukewarm drug launches and a fizzled out weight-loss play, Pfizer is focusing on cost-cutting and reinvesting in new drug research in hopes that it ...

Barely a year after the U.S. FDA shackled Abeona Therapeutics Inc.’s cell-based gene therapy with a complete response letter, the agency has approved it for treating a rare and genetic skin disease.

Pfizer CEO Albert Bourla on Tuesday said uncertainty around President Donald Trump's planned pharmaceutical tariffs is deterring the company from further investing in U.S. manufacturing and ...